Nephris
Research and innovation for diabetic kidney disease
Milan, Italy · Founded 2021 · $3.2M raised
- Headquarters
- Milan
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- nephris.com
- Total Funding
- $3.2M
- Last Round
- $3.2M SeedApr 2022
- Rounds
- 1
About
Nephris is a pre-clinical stage biotech company developing first-in-class therapies for chronic kidney disease in diabetic patients. Founded in 2021 in Milan by Dr. Paolo Fiorina, a professor of endocrinology at the University of Milan, and Dr. Francesca D'Addio, the company focuses on identifying novel pathogenic factors and therapeutic targets in diabetic nephropathy. Nephris is backed by Sofinnova Partners through the Sofinnova Telethon Fund, a fund dedicated to rare and genetic disease biotechnology, and is developing kidney-targeting drug delivery approaches to slow or reverse disease progression.
Summary
Nephris is a Biotech company based in Milan, Italy, founded in 2021. It has raised $3.2M in total across 1 round, most recently a $3.2M Seed round in Apr 2022. Investors include Sofinnova Partners.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2022
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...